SHMARQL

lisdexamfetamine

<http://www.wikidata.org/entity/Q6558704>

chemical compound
rdfs:label
"lisdexamfetamine"@en
skos:altLabel
"(2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamid"@de
"Vyvanse"@de
schema:description
"chemical compound"@en
schema:dateModified "2026-11-09T16:43:17+00:00"^^xsd:dateTime
schema:version 2567203828
wikibase:identifiers 31
wikibase:sitelinks 30
wikibase:statements 69
p:P10245 wd:statement/Q6558704-e5970ce2-4964-18e0-bf39-0632c6936799
p:P11089 wd:statement/Q6558704-3F846244-5812-4574-A850-FE46D169AC55
p:P11143 wd:statement/Q6558704-61937BB5-95F9-4843-8812-6F603FBFFCC3
p:P11198 wd:statement/Q6558704-5BB93C97-629C-4ACC-95DF-5A2AB56E92A6
p:P11199 wd:statement/Q6558704-0BEB9EEC-646E-4BFF-8AB4-40A7AD3A6A33
p:P117 wd:statement/Q6558704-1a3a480d-4d49-44d3-e1cc-18a264a834d3
p:P1246 wd:statement/Q6558704-F1819787-3A8B-4511-B11F-CD547C5D5446
p:P14834 wd:statement/Q6558704-97D3902C-4B38-4118-992A-BD1A8A1324D8
wd:statement/Q6558704-BF7E352B-26D9-4E1B-9972-D821FF85B57D
wd:statement/Q6558704-DE3B786D-A061-4C67-917B-6C53A3E3F949
wd:statement/Q6558704-F37344F0-5F5A-4324-A3DB-18EDA286B354
wd:statement/Q6558704-F9C9AF5A-504B-4A74-BCF0-C44B1518502D
p:P176 wd:statement/Q6558704-8ae57633-4fe8-f706-f7a9-71dbba0261c4
p:P2017 wd:statement/Q6558704-55A6CC5C-A892-4374-B8B9-3B65365EC05E
p:P2057 wd:statement/Q6558704-D93A0CE2-F3C0-4640-8C24-305ADB22B0BC
p:P2062 wd:statement/Q6558704-4A240DA2-0792-44DA-B982-34BEC255711B
p:P2067 wd:statement/Q6558704-220692F1-2CE5-44AB-91E1-EAC540873853
p:P2115 wd:statement/Q6558704-6D16BDA4-F475-4A1E-BA93-B2A190A7A540
p:P2175 wd:statement/Q6558704-26B1F5DE-6112-4332-8265-416C0CE2797F
wd:statement/Q6558704-40eb7853-4f42-a39e-0345-bc2b8ef2ae24
wd:statement/Q6558704-52017329-4c22-1d24-e598-0b456a8b73f8
p:P2275 wd:statement/Q6558704-C556D510-7B52-41CB-8C4E-6DDBB7555637
p:P231 wd:statement/Q6558704-0F336438-91C8-469A-896E-0077AB7C1A3C
p:P233 wd:statement/Q6558704-26203929-6A9C-41D7-9A58-22F7867D054D
p:P234 wd:statement/Q6558704-D4627F0B-C441-447C-9AD5-7BBB59D93A20
p:P235 wd:statement/Q6558704-42997A14-3E50-4D2E-8B7A-5A8292F2667D
p:P267 wd:statement/Q6558704-ce1d2abb-4e97-f0bf-12d1-ff2d8ea2e72d
p:P274 wd:statement/Q6558704-38282295-F1B5-4262-BC38-6CE1FF6831F3
p:P279 wd:statement/Q6558704-86baaea8-4200-7f43-5707-2737af76f321
wd:statement/Q6558704-F66337DF-6356-4BD1-B452-6E21AC011EF1
wd:statement/Q6558704-aac233f1-4ded-a572-19e8-617be0fddae4
p:P2868 wd:statement/Q6558704-1B0AA24F-46EF-4346-A2EF-AA6772A26CA3
wd:statement/Q6558704-F1CC57AB-3779-45AD-9CF5-831BFBB6FF59
p:P2877 wd:statement/Q6558704-AC0806AA-4FB4-4BC4-9DE5-42C27635A045
p:P2892 wd:statement/Q6558704-9278B41F-2B17-4C4B-8230-5A94E9FD6ECB
p:P31 wd:statement/Q6558704-F7492B95-5CDA-4930-8241-AD358E5CD5C1
p:P3117 wd:statement/Q6558704-C9FD1D8B-C2BD-4366-BD35-F0D77F0B89B2
p:P3345 wd:statement/Q6558704-78122DC4-1674-4937-9501-6712FBCCA615
p:P3417 wd:statement/Q6558704-AC472669-6432-4D91-903B-569416EC3799
p:P3489 wd:statement/Q6558704-65A32187-F40D-4854-8AFF-6F031EADAA10
wd:statement/Q6558704-DF5C1918-C10B-45E6-B20E-4E31CB4A9C48
p:P3493 wd:statement/Q6558704-586171B6-6833-48B9-BEB4-B753BD7F5FF1
p:P366 wd:statement/Q6558704-E896DAC6-6DA0-4AEC-ADE0-5BA789A7E571
p:P373 wd:statement/Q6558704-5799897A-166B-40B5-A89D-E638C63AA463
p:P3780 wd:statement/Q6558704-45179f7f-4b90-eb1c-910b-686d207ea405
wd:statement/Q6558704-6403ADF4-29BC-4574-9FBC-D0FC094D0A30
wd:statement/Q6558704-cb779782-4f8f-f9ce-a81f-c42520fa5ae2
wd:statement/Q6558704-e727a1b5-4f00-ed5c-c218-2e1c9853df0f
p:P4235 wd:statement/Q6558704-56E3A608-8E03-481B-A946-A09F98922EC3
p:P4250 wd:statement/Q6558704-39B6FB6D-F3ED-45D7-AD5F-5B8FCAE1D606
p:P4527 wd:statement/Q6558704-98da475f-4c24-0e1e-be08-300749ea7b49
p:P592 wd:statement/Q6558704-275EA8F4-820B-453A-84D7-0AEBBCD43780
p:P595 wd:statement/Q6558704-EA818DCF-4CEE-4B23-A24D-B23D6414EDA8
p:P6366 wd:statement/Q6558704-1474E743-B984-487A-BE9C-FEF3C2DC59F4
p:P646 wd:statement/Q6558704-0B244BB1-5B5F-4DE4-A6E1-9F976117AA25
p:P652 wd:statement/Q6558704-64A2F917-D8AA-4E06-9CBB-DC379EEE942A
p:P661 wd:statement/Q6558704-459C38AF-4B15-4B77-B945-CC3E549F4B66
p:P662 wd:statement/Q6558704-FAFC8E52-ECC1-40D9-8F7E-A422384FEDE2
p:P6694 wd:statement/Q6558704-893CB6A5-9986-4048-A52A-63C928E62E28
p:P683 wd:statement/Q6558704-D987B454-5BD4-46D9-BAD4-41AC3CDCE67F
p:P715 wd:statement/Q6558704-D6794F0C-A6BD-492B-BBEE-34A750D1FC09
p:P8224 wd:statement/Q6558704-f57cdd20-432f-58ae-6204-f154460b4f78
p:P8494 wd:statement/Q6558704-AF67C9FF-EC33-4C2D-B4A8-3B391B815CCF
p:P973 wd:statement/Q6558704-2135B069-B2BE-4460-9ED0-5A63AD0AF999
wd:statement/Q6558704-403B73C7-88E0-4A02-BDB2-79C2AC5BA3CB
wd:statement/Q6558704-659DD2E7-C523-4077-8B7E-D4C3414A9C7C
wd:statement/Q6558704-CF8E3D20-544F-41AE-9437-6B004BBF6A83
wd:statement/Q6558704-F4E2357A-4F78-430A-8CF6-D8E78FFBDC95
wd:statement/Q6558704-F8BCC617-FCC0-4455-92A8-37934AD009EA
p:direct-normalized/P2115 <http://purl.bioontology.org/ontology/NDFRT/N0000176089>
p:direct-normalized/P4527 <http://data.parliament.uk/terms/460550>
p:direct-normalized/P592 <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1201222>
p:direct-normalized/P6366 <https://makg.org/entity/2781303067>
p:direct-normalized/P661 <http://rdf.chemspider.com/9772458>
p:direct-normalized/P662 <http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11597698>
p:direct-normalized/P6694 <http://id.nlm.nih.gov/mesh/M0583181>
p:direct-normalized/P683 <http://purl.obolibrary.org/obo/CHEBI_135925>
wdt:P10245 "a607047"
wdt:P11089 "165726"
wdt:P11143 "Lisdexamfetamine"
wdt:P11198 "4135"
wdt:P11199 "PD009934"
wdt:P117 <http://commons.wikimedia.org/wiki/Special:FilePath/Lisdexamfetamine%20structure.svg>
wdt:P1246 "EP1644019"
wdt:P14834 Schedule I (Russia)
Class B (United Kingdom)
Schedule II (United States)
Anlage III (Germany)
Schedule 8 (Australia)
wdt:P176 Takeda Pharmaceutical Company
wdt:P2017 "C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N"
wdt:P2057 "HMDB0015385"
wdt:P2062 "8277"
wdt:P2067 263.199762^^xsd:decimal
wdt:P2115 "N0000176089"
wdt:P2175 attention deficit hyperactivity disorder
narcolepsy
binge eating disorder
wdt:P2275 "lisdexamfetamine"@en
wdt:P231 "608137-32-2"
wdt:P233 "CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N"
wdt:P234 "InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1"
wdt:P235 "VOBHXZCDAVEXEY-JSGCOSHPSA-N"
wdt:P267 "N06BA12"
wdt:P274 "C₁₅H₂₅N₃O"
wdt:P279 phenyl compound
diamine
N-substituted primary carboxamide
wdt:P2868 serotonergic agent
nootropic
wdt:P2877 "158949"
wdt:P2892 "C1873633"
wdt:P31 type of chemical entity
wdt:P3117 "DTXSID00209652"
wdt:P3345 "700810"
wdt:P3417 "Lisdexamfetamine"
wdt:P3489 US pregnancy category C
Australian pregnancy category B3
wdt:P3493 boxed warning
wdt:P366 medication
wdt:P373 "Lisdexamfetamine"
wdt:P3780 Venvanse
Aduvanz
Elvanse
Vyvanse
wdt:P4235 "lisdexamfetamine"
wdt:P4250 30.0^^xsd:decimal
wdt:P4527 "460550"
wdt:P592 "CHEMBL1201222"
wdt:P595 "7213"
wdt:P6366 "2781303067"
wdt:P646 "/m/02pp41h"
wdt:P652 "H645GUL8KJ"
wdt:P661 "9772458"
wdt:P662 "11597698"
wdt:P6694 "M0583181"
wdt:P683 "135925"
wdt:P715 "DB01255"
wdt:P8224 <http://commons.wikimedia.org/wiki/Special:FilePath/Lisdexamfetamine%20molecule%20ball.png>
wdt:P8494 "DTXCID50132143"
wdt:P973 <https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa/00010289/202002_en.pdf>
<https://www.ipo.gov.uk/p-find-spc-byspc-results.htm?number=SPC/GB13/052>
<https://www.ipo.gov.uk/p-ipsum/Case/PublicationNumber/EP1644019>
<https://www.medicalnewstoday.com/articles/vyvanse#side-effects>
<https://www.medicines.org.uk/emc/product/6828/smpc#gref>
<https://www.patientslikeme.com/treatment/lisdexamfetamine>
Download as:
TurtleJSON-LDRDF/XML
data from SPARQL profile: Wikidata